All In Biotech

Free tool

FAERS Monitor: Fluorescein Sodium and Benoxinate Hydrochloride

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211039 or its brand name (Fluorescein Sodium and Benoxinate Hydrochloride, Benoxinate Hydrochloride, Fluorescein Sodium). Reports on generic versions are filed under their own applications.

Reports

3

Serious

3

100% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • syncope2
  • abdominal pain upper1
  • blood glucose decreased1
  • confusional state1
  • disorientation1
  • dizziness1
  • dysarthria1
  • dyspnoea1
  • fatigue1
  • feeling hot1
  • headache1
  • heart rate increased1
  • hydronephrosis1
  • hypotension1
  • lower respiratory tract congestion1

Reports by year received

View as table
YearReports
20151
20191
20241

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,156 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
lower respiratory tract congestion14125.8832.11,030
hydronephrosis1936.5189.0233
dysarthria1186.237.646
disorientation1177.035.743
blood glucose decreased1146.029.536
syncope2140.163.0155
feeling hot1114.423.128
heart rate increased170.814.317
confusional state143.48.810
hypotension135.07.18
abdominal pain upper134.16.98
dizziness114.12.83
dyspnoea112.42.52
headache111.22.32
fatigue19.01.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.